Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The investigators aim to determine the effect of suvorexant on actigraphically-derived total
sleep time in patients with effectively treated restless legs syndrome with persistent
insomnia in a two-arm, double-blind, randomized placebo-controlled crossover 2.5-month trial.